Crispr Therapeutics AG vs Etsy Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Etsy Inc trades at $80 (market cap $7.29B). The key difference: Etsy Inc is the larger of the two by market cap, and Etsy Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ETSY | |
|---|---|---|
Market Cap | $5.23B | $7.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $86.47 |
52-Week Low | $44.34 | $44.05 |
Enterprise Value | $3.65B | $9.25B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
ETSY trades at $79.42, down 1.22% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and raised its full-year outlook while announcing a 12% workforce reduction and a $2 billion share repurchase program. Revenue for 2025 was $2.88 billion with a net income margin of 5.65%, though equity remains negative at -$758.87 million due to retained earnings deficits.
The outlook is mixed: analyst consensus is a Buy with a $85.71 price target, reflecting optimism on operational efficiency and AI-driven growth, but risks include high debt, negative equity, and competitive pressures. The stock's valuation metrics like P/E of 25.15 and P/S of 3.54 suggest moderate pricing relative to peers, with cash flow stability from operations offering support amid restructuring.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →